Navigation Links
Report Regarding the Managements' and Closely Related Parties' Transactions With Securities in Exiqon A/S
Date:9/2/2008

VEDBAEK, Denmark, September 2 /PRNewswire-FirstCall/ -- Pursuant to section 28a of the Danish Securities Trading Act, Exiqon A/S is required to publish the managements' and their closely related parties' transactions with shares and related securities in Exiqon A/S.

Name: Per Wold-Olsen

Reason for reporting: Member of Exiqon's Board

of Directors

Security Code (ISIN-kode): DK0060077758

Name of the securities: Share

Type of transaction: Buy

Date of trade 2 September 2008

Place of transaction: OMX Nordic Exchange

Copenhagen

Traded securities (no.): 10.000

Market value in DKK of traded 270.000,00

securities:

About Exiqon

Exiqon is dedicated to personalizing the treatment selection for cancer patients. Our goal is to optimise the use of existing medicine and avoid unnecessary and non-effective treatment. We aim to achieve this through improved diagnosis: by using diagnostic tests that analyses the genetic profile of each patient's tumour, we can help optimise the treatment selection for the individual patients. Exiqon is uniquely positioned to develop such new diagnostic tests, and we possess the necessary technology. The technology is referred to as LNA(TM). Using this technology, over a period of only four years Exiqon has been able to establish a position for itself as one of the market's leading providers of research products for gene expression analysis.

Our research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other disorders such as neurological disorders and metabolic diseases.

We are currently developing our new molecular diagnostic products, and the first new product based on the LNA(TM) technology is scheduled for launched by the end of 2008. A number of new products will follow in the years ahead. Exiqon already has a significant market presence through its existing diagnostic product sales to hospitals in the USA. Through Oncotech, Exiqon markets diagnostic products that enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and helps them select an efficacious treatment. Oncotech is the market leader when it comes to selling such diagnostic tests based on an analysis of fresh tumour tissue. Exiqon plans to use Oncotech's leading market position to sell our new molecular diagnostic products based on the LNA(TM) technology.

Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorised as a biotech company (Small Cap+).

Disclaimer

Forward-looking statements:

This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.


'/>"/>
SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
2. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
3. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
6. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
7. MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative
8. GlaxoSmithKline To Post Quarterly US Grants Report
9. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
10. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):